What Bloodwork to Get Before, During & After a Peptide Protocol (2026)
⚡ Quick Answer
Essential labs before any peptide protocol: Comprehensive metabolic panel (CMP), complete blood count (CBC), lipid panel, fasting glucose + HbA1c, thyroid (TSH), and sex hormones (testosterone, estradiol, LH, FSH). Add IGF-1 before GH peptides. Add liver enzymes before SARMs or steroids.
When to retest: At 8 weeks (mid-protocol) and 16 weeks (end of first full cycle). Ongoing every 3–6 months for long-term users. Labs are not optional — they are how you know your protocol is working and how you catch problems early.
Why Bloodwork Is Non-Negotiable
Peptides work by modifying your body’s hormonal and metabolic environment. Without baseline and follow-up bloodwork, you are operating blind — you can’t know whether your protocol is working, whether you need to adjust doses, or whether something is going wrong. Labs serve three critical functions:
- Confirm safety: Catch any adverse effects (liver stress, lipid changes, hormonal disruption) before they become serious
- Confirm efficacy: Objective proof your protocol is producing the intended metabolic changes (HbA1c down, IGF-1 up, testosterone improved)
- Guide dose adjustment: Optimal dosing is individual — bloodwork tells you whether to increase, maintain, or reduce your dose
The Rule of Thumb
If a compound is powerful enough to produce meaningful physiologic change, it is powerful enough to cause problems if used incorrectly. Bloodwork is what separates informed, safe use from guessing. It also gives you objective proof of the results you’re achieving — motivating continued adherence.
Baseline Labs (Before Starting Any Protocol)
These labs apply to every person starting any peptide protocol, regardless of which compounds they plan to use:
Universal Baseline Panel
| Test | What It Measures | Why It Matters |
|---|---|---|
| Comprehensive Metabolic Panel (CMP) | Glucose, kidney function (BUN, creatinine), liver enzymes (AST, ALT, ALP), electrolytes, protein | Establishes kidney and liver baseline; catches pre-existing conditions |
| Complete Blood Count (CBC) | Red cells, white cells, platelets, hemoglobin, hematocrit | Baseline blood health; catches anemia, infection, or clotting issues |
| Lipid Panel | Total cholesterol, LDL, HDL, triglycerides | Baseline cardiovascular risk; GLP-1s improve, SARMs may worsen |
| Fasting Glucose + HbA1c | Current blood sugar + 3-month average | Establishes metabolic baseline; key efficacy marker for GLP-1 peptides |
| TSH (Thyroid) | Thyroid stimulating hormone | Thyroid affects metabolism; some peptides contraindicated in thyroid cancer history |
| Total + Free Testosterone | Available and bound testosterone | Baseline hormonal health; SARMs suppress; fat loss often improves |
| Estradiol (E2) | Primary estrogen | Important for both men (elevated in obesity) and women (menopausal status) |
| LH + FSH | Pituitary hormones controlling sex hormone production | Baseline pituitary function; affected by SARMs |
Additional Labs by Compound Type
GLP-1 Peptides (Semaglutide, Tirzepatide)
| Additional Test | Why | When |
|---|---|---|
| Insulin (fasting) | Measures insulin resistance directly; key efficacy marker | Baseline + week 16 |
| Lipase + Amylase | Pancreatitis screening — GLP-1s have rare pancreatitis association | Baseline; retest if severe abdominal pain develops |
| eGFR (kidney filtration) | GLP-1s protect kidneys but screen function before use | Baseline + week 16 |
| Calcitonin | Thyroid C-cell marker — GLP-1s have theoretical thyroid risk (MTC) | Baseline; contraindicated if elevated |
| Body composition (DEXA or circumference) | Objective fat loss and muscle preservation tracking | Baseline + every 12 weeks |
GH Peptides (Ipamorelin, CJC-1295, Sermorelin, Tesamorelin)
| Additional Test | Why | When |
|---|---|---|
| IGF-1 | Primary efficacy marker for GH peptides — should rise with effective dosing | Baseline + week 8 + week 16 |
| Fasting glucose + insulin | GH can increase insulin resistance at high levels; monitor especially in T2D | Baseline + week 8 |
| IGF-1 ceiling check | Avoid supraphysiologic IGF-1 elevation (>300–350 ng/ml) associated with cancer risk | Week 8 mandatory |
SARMs (Ostarine, LGD-4033, RAD-140, etc.)
| Additional Test | Why | When |
|---|---|---|
| AST + ALT (liver enzymes) | SARMs can elevate liver enzymes — the most common adverse effect | Baseline + week 4 + week 8 + 4 weeks post-cycle |
| Total + free testosterone | SARMs suppress testosterone — measure degree of suppression | Baseline + mid-cycle + 4 weeks post-cycle (recovery check) |
| HDL cholesterol | SARMs reduce HDL — most significant cardiovascular risk factor | Baseline + week 8 |
| SHBG | SARMs reduce SHBG; affects free testosterone calculation | Baseline + week 8 |
When to Test: The Complete Testing Schedule
| Timepoint | Tests Required | Purpose |
|---|---|---|
| Before starting (Baseline) | Full universal panel + compound-specific additions | Establish baseline; screen contraindications; reference point |
| Week 4 (SARMs only) | Liver enzymes (AST/ALT), testosterone | Early safety check for SARMs; catch liver stress early |
| Week 8 (Mid-protocol) | Full panel repeat + compound-specific markers | Confirm safety; assess efficacy; guide dose adjustment |
| Week 16 (End of cycle) | Full panel + body composition | Confirm outcomes; document results; plan next cycle |
| 4 weeks post-cycle | Testosterone, LH/FSH (SARMs/steroids); IGF-1 (GH peptides) | Confirm hormonal recovery; verify return to baseline |
| Ongoing (long-term users) | Full panel every 3–6 months | Chronic safety monitoring for continuous protocols |
Interpreting Key Results
| Marker | Direction You Want | Red Flag (Act Immediately) |
|---|---|---|
| HbA1c | ↓ Decrease (GLP-1 efficacy) | >8% or rising despite treatment |
| IGF-1 | ↑ Rise into upper-normal range | >300–350 ng/ml (supraphysiologic) |
| AST / ALT | Stable or improving | >3× upper limit of normal |
| LDL cholesterol | ↓ Decrease (GLP-1 effect) | Significant rise (>30% above baseline) with SARMs |
| HDL cholesterol | ↑ Increase (GLP-1 effect) | >30% drop from baseline (SARMs) |
| Total testosterone | Stable or rising | <200 ng/dl with symptoms |
| Fasting glucose | ↓ Decrease (GLP-1 effect) | >126 mg/dl (diabetes range) if not already diabetic |
| eGFR (kidney) | Stable or improving | <60 ml/min/1.73m² (kidney disease range) |
Frequently Asked Questions
Where do I get bloodwork without a doctor’s prescription?
In the US, direct-to-consumer lab testing is available through services like LabCorp OnDemand, Quest Diagnostics (direct), Ulta Lab Tests, and Walk-In Lab. These allow you to order your own panels online, visit a local draw site, and receive results without a physician’s order. Costs are typically $50–200 for a comprehensive panel depending on tests ordered. Always follow up with a healthcare provider if results show concerning values.
What if I can’t afford comprehensive bloodwork?
What’s the most important single test for GH peptide users?
IGF-1. It’s the primary downstream marker of GH activity and tells you both whether your peptide is working (efficacy) and whether you’re exceeding safe GH levels (safety). A mid-protocol IGF-1 check at week 8 is the single most valuable test for anyone using Ipamorelin, CJC-1295, Sermorelin, or Tesamorelin. Target: upper-normal for age, typically 150–280 ng/ml for adults 30–50.
How do I know if my GLP-1 peptide is actually working?
Three objective markers: (1) HbA1c reduction of 0.5–2%+ at week 16 (best long-term metabolic marker), (2) fasting glucose normalization, and (3) body weight and waist circumference measurements. Don’t rely solely on scale weight — DEXA or waist measurements confirm fat loss vs muscle loss. For a full guide on peptide results monitoring, see our beginner’s guide.
📚 References
- American Association of Clinical Endocrinology. “Comprehensive Metabolic Monitoring Guidelines.” AACE, 2023.
- Bhasin S. et al. “Testosterone therapy in men with hypogonadism.” JCEM, 2018.
- Lincoff A.M. et al. “Semaglutide cardiovascular outcomes.” NEJM, 2023.
- National Institutes of Health. “IGF-1 reference ranges by age and sex.” NIH/NLM, 2020.
Start Your Protocol the Right Way
Get labs first, then choose your peptides:
Leave a Reply